Diagnostic options · UAE

Neurogenetic tests in Dubai & UAE

Compare available Neurogenetic tests, their listed prices and the information provided for each option. Test selection and preparation should be discussed with your clinician.

Tests in this category

Listed price range

750.00–2,800.00 AED

Clinical preparation

Confirm test-specific instructions with your clinician or laboratory.

Compare available tests

Neurogenetic test prices

Showing 16–30 of 33 matching tests.

Neurogenetic diagnostic tests, details, and listed prices
Test and description	Specimen	Typical duration	Price	Options
TEST-4087 LRSAM1 Gene CMT2P Genetic Test This test identifies pathogenic mutations in the LRSAM1 gene associated with Charcot-Marie-Tooth disease type 2P (CMT2P).	Whole Blood (EDTA), Extracted DNA, or FTA Card Sample	3–4 weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic mutations in the LRSAM1 gene"] Parameters [] Preparation [] Indications ["Clinical suspicion of Charcot-Marie-Tooth disease type 2P", "Family history suggestive of autosomal dominant CMT2P"] Measurement technique Confirm with laboratory Codes LOINC: 94219-8 ICD-10: G60.0 Clinical summary This test identifies pathogenic mutations in the LRSAM1 gene associated with Charcot-Marie-Tooth disease type 2P (CMT2P).
TEST-4314 MECP2 Gene (Neonatal Severe Encephalopathy) Genetic Test This test identifies pathogenic variants within the MECP2 gene associated with severe early-onset encephalopathy and related neurodevelopmental disorders.	Peripheral Whole Blood or Dried Blood Spot (FTA Card)	3 – 4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the MECP2 gene"] Parameters [] Preparation [] Indications ["Neonatal Encephalopathy", "Rett Syndrome", "Atypical Rett Syndrome", "MECP2 Duplication Syndrome"] Measurement technique Confirm with laboratory Codes LOINC: 95162-5 ICD-10: G93.4 Clinical summary This test identifies pathogenic variants within the MECP2 gene associated with severe early-onset encephalopathy and related neurodevelopmental disorders.
TEST-4822 MEF2C Gene Intellectual Disability (Autosomal Dominant Type 20) Genetic Test This genetic test identifies pathogenic variants in the MEF2C gene associated with autosomal dominant intellectual disability type 20.	Whole Blood (EDTA), Buccal Swab, FTA Card / Dried Blood Spot	3 – 4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the MEF2C gene"] Parameters [] Preparation ["No specific fasting required", "Inform lab of any anti-epileptic or centrally acting medications"] Indications ["Children and adults with moderate-to-severe global developmental delay", "Early-onset epilepsy (infantile spasms, myoclonic seizures)", "Absent or severely limited speech", "Stereotypic hand movements", "Distinctive craniofacial features", "Family history of MEF2C-related disorder", "Parents planning future pregnancies after an affected child", "Asymptomatic first-degree relatives seeking carrier status clarification"] Measurement technique Confirm with laboratory Codes LOINC: 93359-8 ICD-10: F78.9, G40.909, Z15.89 Clinical summary This genetic test identifies pathogenic variants in the MEF2C gene associated with autosomal dominant intellectual disability type 20.
TEST-4025 MPZ Gene (CMT2I) Genetic Test This test evaluates the MPZ gene for pathogenic variants associated with Charcot-Marie-Tooth disease type 2I.	Peripheral Whole Blood (3-5 mL in EDTA tube)	3-4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the MPZ gene", "Copy number variations in the MPZ gene"] Parameters [] Preparation ["No fasting required", "Provide previous neurological reports", "Genetic counselling is mandatory before testing"] Indications ["Suspected Charcot-Marie-Tooth disease type 2I", "Family history of CMT2I", "Evaluation of hereditary neuropathy"] Measurement technique Confirm with laboratory Codes LOINC: 74421-8 ICD-10: G60.0 Clinical summary This test evaluates the MPZ gene for pathogenic variants associated with Charcot-Marie-Tooth disease type 2I.
TEST-4132 MPZ Gene Dejerine‑Sottas Disease Genetic Test This genetic test analyzes the MPZ gene for mutations associated with Dejerine‑Sottas disease and related hereditary neuropathies.	Whole Blood (peripheral) or FTA Card Blood Spot	3 – 4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the MPZ gene", "Copy number variations in the MPZ gene"] Parameters [] Preparation [] Indications ["Clinical suspicion of Dejerine‑Sottas disease (CMT1A)", "Clinical suspicion of Charcot‑Marie‑Tooth type 1B (CMT1B)", "Family history of hereditary neuropathy", "Congenital hypomyelination"] Measurement technique Confirm with laboratory Codes LOINC: 48018-5 ICD-10: G60.0 Clinical summary This genetic test analyzes the MPZ gene for mutations associated with Dejerine‑Sottas disease and related hereditary neuropathies.
TEST-5774 PDYN Gene Spinocerebellar Ataxia Type 23, Autosomal Dominant Genetic Test This test detects pathogenic single-nucleotide variants, small insertions/deletions, and copy number variants within the PDYN gene to diagnose Autosomal Dominant Spinocerebellar At...	Peripheral Whole Blood (EDTA)	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the PDYN gene", "Single-nucleotide variants (SNVs)", "Small insertions/deletions (indels)", "Copy Number Variants (CNVs)"] Parameters [] Preparation ["No fasting required", "Continue all prescribed medications unless directed otherwise", "Mandatory pre-test genetic counselling session required"] Indications ["Diagnosis of suspected SCA23", "Pre-symptomatic testing in at-risk family members", "Genetic counselling for families with SCA23", "Differentiation from other spinocerebellar ataxia subtypes"] Measurement technique Confirm with laboratory Codes LOINC: 21636-6 ICD-10: G11.8 Clinical summary This test detects pathogenic single-nucleotide variants, small insertions/deletions, and copy number variants within the PDYN gene to diagnose Autosomal Dominant Spinocerebellar Ataxia Type 23.
TEST-5851 PPP2R2B Gene Spinocerebellar Atrophy Type 12 (SCA12) Autosomal Dominant Genetic Test This genetic test identifies pathogenic variants in the PPP2R2B gene, confirming or ruling out the genetic basis for Spinocerebellar Ataxia Type 12 (SCA12).	Whole blood (EDTA), extracted DNA, or DNA FTA card	3–4 weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the PPP2R2B gene", "Presence of mutations causing SCA12"] Parameters [] Preparation ["No specific fasting required", "Inform lab of any medications"] Indications ["Diagnosis of SCA12 in symptomatic individuals", "Presymptomatic testing in at-risk individuals", "Carrier screening in families with SCA12 history", "Family planning"] Measurement technique Confirm with laboratory Codes LOINC: 51969-4 ICD-10: G11.2 Clinical summary This genetic test identifies pathogenic variants in the PPP2R2B gene, confirming or ruling out the genetic basis for Spinocerebellar Ataxia Type 12 (SCA12).
TEST-5601 RAI1 Gene Smith‑Magenis Syndrome Genetic Test This test evaluates the RAI1 gene for pathogenic variants associated with Smith‑Magenis syndrome.	Peripheral Blood (Whole Blood or Plasma) on FTA Card	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["RAI1 gene sequence", "Point mutations", "Small insertions/deletions", "Copy number variations"] Parameters [] Preparation [] Indications ["Diagnosis of Smith‑Magenis syndrome", "Carrier screening", "Family planning"] Measurement technique Confirm with laboratory Codes LOINC: 81320-6 ICD-10: Q87.19 Clinical summary This test evaluates the RAI1 gene for pathogenic variants associated with Smith‑Magenis syndrome.
TEST-3743 RNASEH2C Gene Aicardi‑Goutières Syndrome Type 3 Genetic Test This test identifies pathogenic variants in the RNASEH2C gene to confirm a diagnosis of Aicardi-Goutières syndrome type 3 (AGS3).	Peripheral whole blood (3–5 mL in EDTA tube)	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the RNASEH2C gene"] Parameters [] Preparation ["No special preparation is required"] Indications ["Confirmation of Aicardi-Goutières syndrome type 3 (AGS3)", "Early neurological intervention", "Family planning", "Recurrence risk counseling"] Measurement technique Confirm with laboratory Codes LOINC: 85468-8 ICD-10: G31.89 Clinical summary This test identifies pathogenic variants in the RNASEH2C gene to confirm a diagnosis of Aicardi-Goutières syndrome type 3 (AGS3).
TEST-3096 SCA‑23 (Spinocerebellar Ataxia): PDYN Gene Mutation Test This test identifies pathogenic mutations in the PDYN gene, confirming a diagnosis of Spinocerebellar Ataxia type 23 (SCA-23).	Whole blood (EDTA lavender top)	Report within 5 working days (sample received by Tuesday 11 AM yields report by Saturday)	1,500.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the PDYN gene"] Parameters [] Preparation ["A duly filled Genomics Clinical Information Requisition Form (Form 20) is mandatory before sample processing."] Indications ["Clinical suspicion of SCA-23", "Family history of SCA-23"] Measurement technique Confirm with laboratory Codes LOINC: 94259-4 ICD-10: G11.8, G11.1, Z15.89 Clinical summary This test identifies pathogenic mutations in the PDYN gene, confirming a diagnosis of Spinocerebellar Ataxia type 23 (SCA-23).
TEST-4997 SLC9A6 Gene Christianson Syndrome (X-linked Intellectual Disability) Genetic Test This genetic test identifies pathogenic variants in the SLC9A6 gene, confirming a diagnosis of Christianson syndrome.	Whole blood (EDTA)	3–4 weeks from sample receipt	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the SLC9A6 gene", "Copy Number Variations (CNV) in SLC9A6"] Parameters [] Preparation ["No specific patient preparation required"] Indications ["Suspected Christianson syndrome", "X-linked intellectual disability", "Family history of Christianson syndrome"] Measurement technique Confirm with laboratory Codes LOINC: 93101-1 ICD-10: Q87.89 Clinical summary This genetic test identifies pathogenic variants in the SLC9A6 gene, confirming a diagnosis of Christianson syndrome.
TEST-5642 SPG21 Gene Genetic Test This test evaluates the SPG21 gene for pathogenic variants associated with Autosomal Recessive Spastic Paraplegia type 21.	Peripheral Blood	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the SPG21 gene"] Parameters [] Preparation ["Do not discontinue prescribed medication without consulting your doctor"] Indications ["Individuals with progressive lower limb spasticity or gait disturbance", "Family history of autosomal recessive spastic paraplegia", "Unexplained stiffness and weakness in the legs", "Asymptomatic carriers assessing reproductive risks"] Measurement technique Confirm with laboratory Codes LOINC: 81247-9 ICD-10: G11.4 Clinical summary This test evaluates the SPG21 gene for pathogenic variants associated with Autosomal Recessive Spastic Paraplegia type 21.
TEST-3090 Spinocerebellar Ataxia Type 12 (SCA12) PPP2R2B Gene Mutation Test This test identifies the specific CAG trinucleotide repeat expansion in the PPP2R2B gene, confirming or excluding a diagnosis of Spinocerebellar Ataxia Type 12.	Whole Blood (4 mL Lavender-top EDTA tube)	10–12 Business Days	750.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["CAG trinucleotide repeat expansion", "PPP2R2B gene sequence"] Parameters [{"name": "CAG Repeat Length", "reference_range": " Preparation ["Remain well-hydrated", "Maintain regular diet unless instructed otherwise", "Ensure Genomics Clinical Information Requisition Form (Form 20) is filled and signed"] Indications ["Suspected Spinocerebellar Ataxia Type 12", "Familial risk assessment for SCA12"] Measurement technique Confirm with laboratory Codes LOINC: 83746-8 ICD-10: G11.2 Clinical summary This test identifies the specific CAG trinucleotide repeat expansion in the PPP2R2B gene, confirming or excluding a diagnosis of Spinocerebellar Ataxia Type 12.
TEST-4338 SPTAN1 Gene Early Infantile Epileptic Encephalopathy Type 5 Genetic Test This genetic test evaluates the SPTAN1 gene for pathogenic variants associated with Early Infantile Epileptic Encephalopathy Type 5 (EIEE5).	Peripheral Whole Blood (EDTA) or FTA Card (Dried Blood Spot)	3–4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["Pathogenic variants in the SPTAN1 gene"] Parameters [] Preparation [] Indications ["Clinical suspicion of Early Infantile Epileptic Encephalopathy Type 5 (EIEE5)", "Relevant family history"] Measurement technique Confirm with laboratory Codes LOINC: 80772-9 ICD-10: G40.4 Clinical summary This genetic test evaluates the SPTAN1 gene for pathogenic variants associated with Early Infantile Epileptic Encephalopathy Type 5 (EIEE5).
TEST-3761 ST3GAL5 Gene Amish Infantile Epilepsy Syndrome Genetic Test This test detects pathogenic variants in the ST3GAL5 gene, confirming a diagnosis of Amish Infantile Epilepsy Syndrome.	Whole Blood (EDTA), Extracted DNA, or FTA Card Dried Blood Spot	3 to 4 Weeks	2,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["ST3GAL5 gene pathogenic variants", "Full coding region and deep intronic boundaries"] Parameters [] Preparation ["Clinical history review", "Genetic counselling session", "Three-generation pedigree chart construction"] Indications ["Clinical suspicion of Amish Infantile Epilepsy Syndrome", "Early-onset epileptic encephalopathy", "Unexplained seizures in early infancy"] Measurement technique Confirm with laboratory Codes LOINC: 21666-9 ICD-10: G40.4 Clinical summary This test detects pathogenic variants in the ST3GAL5 gene, confirming a diagnosis of Amish Infantile Epilepsy Syndrome.

Category overview

Neurogenetic: overview

Pinpointing the exact hereditary cause of a progressive movement disorder, severe neuropathy, or early-onset cognitive decline is essential for unlocking the most effective neurological care available. As a highly focused diagnostic tool in our Molecular Genetics department, Neurogenetic testing specifically targets the exact DNA mutations responsible for your family's unique neurological challenges. By leveraging advanced sequencing technology, this precise genomic screening confirms conditions like inherited ataxias or early-onset Alzheimer's, providing the critical data necessary to assess carrier status, evaluate risks for future children, and safely guide tailored neurological interventions and access to precision therapies. Highly regarded for specialized diagnostic excellence among the best diagnostic labs in the UAE, DNA Labs guarantees strict patient confidentiality, exceptional analytical precision, and remarkably fast turnaround times. Take control of your long-term brain health—schedule your neurogenetic testing in UAE, coordinate a comfortable home sample collection, or consult our expert medical professionals.

Before booking

Use the test details as a conversation starter

The right diagnostic option depends on your reason for testing and individual circumstances. Check the listed specimen and timing, then confirm any preparation requirements with the ordering clinician or laboratory before collection.